BSE: GLAXO - GlaxoSmithKline Pharmaceuticals Limited

Rentabilidade por seis meses: -6.3%
Rendimento de dividendos: +1.80%

Cronograma de promoção GlaxoSmithKline Pharmaceuticals Limited


Sobre a empresa GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally.

mais detalhes
The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

ISIN INE159A01016
Industry Pharmaceuticals
Sector Health Care
Валюта inr
Валюта отчета inr
Див.доход ао 1.17
Дивиденд ао 44
Сайт https://india-pharma.gsk.com
Цена ао 2657.45
Alteração de preço por dia: -0.2201% (2657.45)
Alteração de preço por semana: -3.63% (2751.5)
Alteração de preço por mês: +30.52% (2031.5)
Alteração de preço em 3 meses: +17.62% (2254.45)
Mudança de preço em seis meses: -6.3% (2830)
Mudança de preço por ano: +35% (1964.15)
Mudança de preço em 3 anos: +73.38% (1529.4)
Mudança de preço em 5 anos: +59.39% (1663.55)
Mudança de preço em 10 anos: 0% (2651.6)
Mudança de preço desde o início do ano: +16.07% (2284.5)

Subestimação

Nome Significado Nota
P/S 9.66 1
P/BV 18.71 1
P/E 56.38 2
EV/EBITDA 24.13 5
Total: 4.5

Eficiência

Nome Significado Nota
ROA, % 17.14 5
ROE, % 33.53 9
Total: 4.5

Dividendos

Nome Significado Nota
Div yield, % 1.8 4.5
DSI 0.8571 8.57
Total: 3.95

Obrigação

Nome Significado Nota
Debt/EBITDA 0.0172 10
Total: 10

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 6.74 1
Rentabilidade Ebitda, % 23.53 4
Rentabilidade EPS, % 11.29 2
Total: 5

Supervisor Cargo Pagamento Ano de nascimento
Mr. Bhushan Akshikar MD & Executive Director 32.37M
Mr. Juby Chandy Whole-Time Director & CFO 54.12M 1977 (48 anos)
Mr. Amit G. Pandey Executive Vice President of Legal N/A
Ms. Simrat Sohal Vice President of Ethics & Compliance N/A
Mr. Chinmay Sharma Executive Vice President of Human Resources N/A
Ms. Sukanya Choudhary Executive Vice-President of Regulatory Affairs N/A
Ms. Aparajita Rajput Vice President of Technology
Mr. Ajay Avinash Nadkarni VP of Administration & Real Estate and Company Secretary
Mr. Ransom D'Souza Executive Vice President of Communications & Government Affairs
Mr. Shourov Mukherjee Executive Vice-President of Adult Vaccines

Endereço: India, Mumbai, GSK House - abrir no Google Maps, abrir mapas Yandex
Site: https://india-pharma.gsk.com